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ABSTRACT (Maxlnwm 200 Words)
Vascular Endothelial Growth Factor (VEGF) is a critical mediator of blood vessel formation during development and in pathological conditions. In this study, we demonstrate that VEGF bioavailability is regulated extracellularly by matrix metalloproteinases (MMPs) through intramolecular processing. Specifically, we show that a subset of MMPs can cleave matrix-bound isoforms of VEGF, releasing soluble fragments. We have mapped the region of MMP processing, generated recombinant forms that mimic MMP-cleaved and MMPresistant VEGF, and explored their biological impact in tumors. Although all forms induced similar VEGF receptor 2 (VEGFR2) phosphorylation levels, the angiogenic outcomes and impact on tumor growth were distinct. MMP-cleaved VEGF promoted capillary dilation of existent vessels but mediated a marginal neovascular response within the tumor. In contrast, MMP-resistant VEGF supported extensive growth of thin vessels with multiple and frequent branch points. Interestingly, MMP-resistant VEGF tumors grew faster and bigger, while MMP-cleaved VEGF tumors grew slower, smaller and macrospically pale. Our findings support the view that matrix-bound VEGF and non-tethered VEGF provide different signaling outcomes and, extracellular VEGF processing offers an important mode for regulation in soluble versus bound VEGF levels in addition to splicing events. Complete or partial suppression of vascular growth by a number of different strategies has been consistently associated with suppression of tumor expansion and tumor growth. Vascular endothelial growth factor (VEGF) signaling pathway is a vital component of pathological angiogenesis during tumor growth and metastasis as alterations in VEGF levels or in receptor phosphorylation leads to suppression of vascular expansion and reduction of tumor growth and metastasis Kim et al., 1993) .
During development, there seems a minimal tolerance to alterations in VEGF expression levels. Inactivation of only one allele results in embryonic lethality at midgestation due to severe cardiovascular defects (Carmeliet et al., 1996; and organ-specific increase of VEGF by 2-fold can also lead to lethality (Miquerol et al., 2000) . Thus, both slight decrease and increase in VEGF levels results in significant pathological effects to the vasculature and to the organism as a whole.
In human, VEGF-A exists as four different isoforms (VEGF 12 1 , VEGF 16 5 , VEGF 1 89 and VEGF 2 0 6 ) that are generated by alternative splicing of a single pre-mRNA. The isoforms differ in their ability to bind to heparan sulfate and to extracellular matrix (ECM) molecules. Only the VEGF 1 2 1 is highly soluble and all other variants bind to extracellular matrix proteins restricting access of the growth factor to VEGF receptors on endothelial cells. VEGF release from matrix stores is thought to be mediated by matrix metalloproteinases (MMPs) and other extracellular proteases which cleave the ECM molecules to release the intact VEGF from ECM stores. During this fellowship I have demonstrated that VEGF bioavailability is regulated extracellularly by MMPs through intramolecular processing.
Body -Results
This Annual Summary summarizes the research accomplished for the period of April 16, 2002 -April 14, 2005 under the Fellowship Grant number DAMD17-02-1-0328.
In short, I demonstrated that ECM-bound VEGF is cleaved intramolecularly by a subset of MMPs. Extracellular cleavage of VEGF results in the release of soluble, receptorbinding domain from the ECM-binding motif. In addition, I showed that the state of free versus bound VEGF dictates whether a vascular network undergo dilation/increased vessel size or will initiate active sprouting events, thus promoting two different modes of vascular expansion in tumor models. These findings have been accepted for publication in the Journal of Cell Biology with the acknowledgment of this grant (see the manuscript in the appendix).
VEGF-A is cleaved by a subset of MMPs. VEGF cleavage by MMPs was tested.
Incubation of VEGF 1 64 with MMP1, 3, 7, 9, 16 and 19 generates 16kDa VEGF fragment (Fig.1A) . Another ECM-bound VEGF-A isoform, VEGF188 is also cleaved by MMP3, generating the same size of VEGF fragment ( . mVEGF, 1 08 1 18 tumor grew faster and bigger than wild-type VEGF tumors, followed by mVEGF 113 tumors (Fig. 4) .
6
Wild Type Hirashima, 2003) . The result is a highly organized and pression of vascular growth and in the concomitant reduction of hierarchical vascular array that is typical of nonpathological tumor mass and metastasis (Kim et al., 1993; Ferrara et al., adult tissues. In contrast, vessel formation in tumors appears 2004) . Unlike most mammalian genes, the inactivation of only much less programmed and is improvised from a limited array one allele results in an embryonic lethality at mid-gestation as a of stimulatory factors (Carmeliet and Jain, 2000: McDonald result of severe cardiovascular defects (Carmeliet et al., 1996; and Choyke, 2003) . Key among these is VEGF . Interestingly, an organ-specific, twofold in- Dvorak, 2002; .
crease of VEGF can also lead to lethality (Miquerol et al., 2000) . VEGF signaling is essential for the specification, morphoThus, alterations of VEGF levels translate into significant pathogenesis, differentiation, and homeostasis of vessels that are in the logical effects on the vasculature and on the organism as a whole. embryo and in the adult Helmlinger et al., Although much emphasis has been placed on understand-2000; Gerber et al., 2002; Ferrara et al., ing the production and stability of VEGF mRNA, relatively little 2003). Furthermore, this signaling pathway is an integral compoattention has been given to the study of the stability and processing of VEGF proteins themselves. Upon secretion, VEGF
Correspondence to M. Luisa Iruelo-Arispe: arispe@mbi.uclo.edu becomes bound to the ECM and is widely Abbreviations used in this paper: CAM, chorioallantoic membrane; HEK, human viewed to act in a paracrine fashion. The interaction of VEGF embryonic kidney; MALDI-TOF MS, matrix-assisted loser desorption time-of-flight with matrix proteins is mediated through the carboxy-terminal MS; MMP, matrix metalloproteinase; tLLC/MS", capillary and microcapillary nano--liquid chromatography MS; ILC/MS/MS, micracapillary reverse-phase region, also known as a heparin-binding or ECM-binding do-HPLC nano-electrospary tandem MS; MS, mass spectrometry; PAE, porcine oarmain (Houck et al., 1991; . The regulation tic endothelial; PAE-VEGFR2, PAE cells expressing VEGFR2; PECAM, platelet/ of VEGF in the extracellular environment has been implicated endothelial cell adhesion molecule 1; TIMP, tissue inhibitor of MPs; VEGFR2, VEGF receptor 2.
in the angiogenic switch, facilitating the transition from hyperThe online version of this article contains supplemental material, plastic to malignant tumor formation .
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Results
and VEGF 1 8) were targeted by MMPs, which generated identi-VEGF is processed by a subset of MMPs cal molecular mass fragments (Fig. I D) .
To test the hypothesis that VEGF could be a substrate of Proteolytic cleavage was inhibited by purified tissue inMMPs, we biotinylated the growth factor and performed a sehibitors of MPs (TIMP) I and TIMP2 (both of which are endogries of in vitro incubations with purified enzymes (Fig. I A) . enous inhibitors of MMP3), but was not inhibited by aprotinin, VEGF,64 was cleaved by MMP3, 7, 9, and 19, releasing a 16-a serine protease inhibitor (Fig. 2 A) . Similarly, digestion by kD fragment. Two additional MMPs (1 and 16) also released MMP9 was blocked by TIMP3 (Fig. 2 B) . Plasmin was previthe fragment, but less effectively. The presence of heparin ously shown to cleave VEGFIs 9 and release this isoform from aided processing by MMP3, but hindered the cleavage of the matrix in a dose-dependent manner ; Keck VEGF by MMP9 (Fig. 1 A) . Glycosylation was not required et al. , 1997) . Fig. 2 A shows that cleavage by plasmin was diffor proteolysis because nonglycosylated VEGFIM4 was cleaved ferent from that generated by MMPs. Plasmin produced a in a similar manner (Fig. 1 B) . Fragments could be detected 5 smaller and less stable fragment than the one resulting from min after exposure to MMP3, as indicated by time course anal-MMP exposure (Fig. 2 A) . Furthermore, cleavage of VEGF by ysis. The cleavage product was stable, and it accumulated over MMP3 also occurred when the growth factor was anchored by time with concomitant reduction in the levels of intact growth heparin. Bound growth factor that was exposed to MMP3 refactor ( Fig. 1 B) . Dose-response analysis also indicated that suited in the release of a soluble 16-kD species (supernatant), the cleavage event occurred in at least two stages. An intermewhereas the 6-kD polypeptide remained bound (Fig. 2 C) . diate species of a higher molecular mass was produced first, To ascertain whether this proteolytic event occurred in and a 13-kD stable fragment (equivalent to the 16-kD fragment vivo, we used human ascites fluid from patients with ovarian from glycosylated growth factor) was subsequently generated, cancer (collected without patient identifiers, under Institutional suggesting the presence of at least two proximal cleavage sites Review Board guidelines). Ascites fluid was collected in the ( Fig. I C) . Interestingly, digestion was found to be optimal at presence of a cocktail of proteinase inhibitors to block cleavage slightly acidic pH (6.9-7.2; Fig. SI 7 minal end of VEGF (amino acid coded by exon 8).
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spedk epitopes that were distributed throughout the entire VEGF proat position 110 . Indeed, this fragment exhibtein, maximizing the retention of all isoforms and fragments.
its a faster mobility (13 kD) than the MMP3 fragment (16 kD; Eluted fractions were combined and were further evaluated with Fig. 3 B) . Furthermore. plasmin proteolyses the small carboxyepitope-specific antibodies. A carboxy-terminal antibody (genterminal, 9-kD fragment to completion (as we have been unerated against residues coded by exon 8; see Fig. 3 A) recogable to detect this fragment with carboxy-terminal antibodies), nized VEGFIS9. VEGFI6, and VEGF 12 1 on immunoblots but in contrast to its presence in samples that are exposed to MMP3 could not detect any cleaved fragments (Fig. 2 D) . This result is (6 kD; Fig. 3 B) . Unlike digestion with MMP3, plasmin-proconsistent with the fact that the residues coded by exon 8 are reduced fragments did not accumulate over time, and levels of moved after VEGF digestion by MMPs [Q1] (as will be the full-length growth factor became reduced, which is an indishown). In contrast, the amino-terminal antibody (see Fig. 3 A) cation of progressive degradation (Fig. S1 B) . was able to detect the intact isoforms (VEGF 1 s 5 and VEGF 121 ) in addition to a group of fragments ranging from 13 to 16kD in MMP-cleaved VEGF fragments ar-able molecular mass (Fig. 2 D) . The fact that only the amino-termito phoephoryate VEfGFR2 and induce nal antibody was able to detect the smaller fragments is consisangiogene5ia tent with the occurrence of proteolysis in the carboxy-terminal
To ascertain whether the fragments were able to elicit receptor region of VEGF. Both plasmin and MMP3 were also detected activation and angiogenesis, we generated a construct that mimin the unfractionated ascites fluid (unpublished data).
icked the MMP-cleaved VEGF protein (VEGF 1 3t) and also deTo further explore whether VEGF was cleaved in vivo.
veloped an MMP-resistant VEGF form (VEGF0j,(%ts; Fig. 3 we devised a dual ELISA system that allowed the distinction C). The latter consisted of a 10-aa deletion between residues between cleaved and intact VEGF based on the selective re-108-118 (Fig. 3 C) . These constructs were used to generate removal of amino acids that are coded by exon 8. Using this syscombinant protein in human embryonic kidney (HEK) 293T tem, we determined that, in fact, 82-90% of circulating VEGF cells and were tested for their susceptibility to MMP3 (Fig. S2 , had been processed, as it lacked the carboxy-terminal domain available at http://www.jcb.org/cgi/content/full/jcb.200409115/ (Fig. 2 E) . DCI). Even though the MMP-resistant VEGF contains aa 120 and 135. which are known to participate in the digestion of Processing of VEGF severs the receptor-VEGFM, it appears that the removal of 108-118 alters the conbinding domain from the extracellualr, formation of the growth factor so that aa 120 and 135 are no matrix-bindi ng motif longer accessible sites for digestion. Next, we mapped the cleavage sites in VEGF using matrix-asSubsequently. porcine aortic endothelial (PAE) cells exsisted laser desorption time-of-flight (MALDI-TOF) mass pressing VEGFR2 (PAE-VEGFR2) were exposed to various spectrometry (MS), capillary and microcapillary nano-liquid purified VEGF forms to evaluate receptor phosphorylation. chromatography MS (IxLC/MS"), and microcapillary reverse-MMP-cleaved and MMP-resistant VEGF forms were similarly phase HPLC nano-electrospary tandem MS (p.LC/MS/MS).
capable of phosphorylating VEGFR2 (Fig. 3 D) . Furthermore, Consistent with electrophoretic mobility evaluations, we found dose-response analysis indicated that the kinetics of phosphothat proteolytic processing takes place in sequential steps. Wirylation were similar to those displayed by wild-type VEGF 1 64 tial cleavage occurs at residues 135, 120, and finally at residue (when isolated in an identical manner). Phosphorylation was 113 (Fig. 3 A) . The events result in the dissociation of the recepdetected at 50 ng and peaked at I Rxg when each one of the tor-binding motif from the ECM-binding domain. This series of three protein forms was used (Fig. 3 D) . More importantly. all proteolytic processing steps is different from those mediated by forms were able to stimulate angiogenesis in the chorioallanplasmin (Fig. 3 B) . Plasmin has been reported to cleave VEGF toic membrane (CAM) assay (Fig. 3 E) . The isoforms were also tested in the Matrigel plug assay work of CAM. Angiogenic growth is stimulated against gravity in mice. Each form was mixed with Matrigel and was injected by growth factors that are embedded in a polymerized matrix subcutaneously; evaluation was performed after 7 d. Once (vitrogen), which is supported by a nylon mesh and placed onto again. all forms elicited an angiogenic response; however, the CAM. The angiogenic response is noted when new vessels inmorphology of the vessels was significantly different (Fig. 3 F) .
vade this acellular matrix, which is subsequently removed from Although VEGFI~, displayed tortuous vessels of simila size to CAM for visualization and quantitation. As seen in Fig. 3 E, a the adjacent vessels in the mouse, VEGFt t 3 showed remarkably vitrogen plug with equivalent levels of the growth factor was enlarged vessels (Fig. 3 F. brackets) . In contrast, Matrigel that placed onto the vascularized CAM. After 24 h, CAM was percontained MMP-resistant VEGF demonstrated thin vessels fused, staine with rhodamine lectin. and the collagen plug was with multiple branch points (Fig. 3 F, arrows) . removed for evaluation under confocal microscopy. InterestFurther exploration of biological effects that are mediated ingly. although all forms elicited an angiogenic response.
by the different VEGF forms was performed in tumor xenograft VEGF 1 1 3 showed fused, enlarged channels (Fig. 3 E, brackets) ; assays. T47D human carcinoma cell lines were transfected with in contrast, MMP-resistant VEGF induced significant sproutexpression vectors that coded for wild-type. MMP-cleaved, ing. resulting in thin, interconnected vessels (Fig. 3 E, (Fig. 4 B (Fig. 4 C) . Together, these findings indicate that ma- Vessels from areas adjacent to the tumor were also affected. In particular, vessels near the tumor-expressing VEGFt1 3 displayed engorged and fragile vessels (Fig. 5) . Ves-VEGF among the different constructs were selected for initial sels in the proximity of MMP-resistant VEGF tumors were also comparison (Fig. 4 A) . Interestingly, we noted high molecular altered, but did not show significant hyperplasia. Instead, we mass bands in the immunoblots from tumor lysates. a finding noted that vessels from MMP-resistant tumors consisted of torthat was reproducible with several antibodies and was suggestuous, thin capillaries, higher vascular density, and groups of tive of macromolecular aggregates that included the growth capillary tufts that were reminiscent of the glomeruli bodies factor. Transfected cells did not show differences in growth (Pettersson et al.. 2000) . Fig. 5 with DME containing serum alone or in the presence of VEGFI, (C) Incorwere dilated and were more heterogeneous in size than vessels poration of increasing levels of BB94 showed a correlation between cord from tumors expressing other VEGF forms.
formation and MMP activity. Bars, 150 jim.
To further dissect the effect of these VEGF forms in capillaxy formation, we evaluated their effects in vitro. Purified and phalloidin staining of the actin cytoskeleton demonstrated growth factors at identical concentrations were included in fiprotrusion of multiple filopodia. Although visual inspection sugbrinogen/fibronectin gels before polymerization. Sepharose gested that VEGF 113 mediated a stronger proliferative response, beads coated with PAE-VEGFR2 cells were mixed with the maa detailed quantitation of endothelial cell proliferation in all three trix as it polymerized and were observed consecutively for 3 d cases did not reveal differences that were statistically significant (Fig. 6 A) . Wild-type VEGFiM elicited the growth of endothelial (Fig. S3 B) . These responses were mediated by VEGFR2. PAE cells as sheets (Fig. 6 A. arrowheads) and induced capillary morcells that were not expressing VEGFR2 did not respond to the phogenesis (Fig. 6 A, arrows) . Interestingly, VEGF1, 3 only ingrowth factor (Fig. 6 B) . The effects were dependent on the presduced the proliferation of endothelial cells as sheets. This conence of VEGF, as PAE-VEGFR2 cells did not respond in a simitrasted with the strong morphogenic events that were mediated lar manner when serum was used instead of VEGF (Fig. 6 B) , by MMP-resistant VEGF (A108-118). In the presence of this Together, the results indicate that in the case of VEGF•I. mutated growth factor, endothelial cells organized into cords, the local, discrete digestion of VEGF is likely to occur as endot- helial cells migrate and grow as sheets, whereas in the absence of of MMPs. Processing results in the release of the receptorsuch digestion, VEGF would mediate the organization of cords.
binding domain from the ECM-binding motif that is present in To test this more directly, we included the broad-spectrum MMP the majority of VEGF-A isoforms. Furthermore. we noted that inhibitor BB94 in the matrix assays and in the culture media. As the state of free versus bound VEGF dictates whether a vascupredicted, we found that the number of cords was increased delar network will undergo dilation/increased vessel size or will pending on the concentration of the MMP inhibitor (Fig. 6 C) .
initiate active sprouting events, thus promoting two different We next sought to determine whether VEGF was cleaved modes of vascular expansion. The first requires the proliferaas cells invaded the matrix. For these experiments, we genertion of cells as sheets, whereas the second entails the initial ated a peptide comprising the MMP cleavage sites that were sensing of the environment by active filopodia extension. miidentified in VEGF16 and a mutant peptide that was not gration/invasion, and subsequent proliferation (Fig. 8) . Overall, cleaved by MMP3 (Fig. 7 A) . Both peptides were conjugated to our findings support the view that matrix-bound and nontethcoumarin (fluorescence) at the amino terminus and to a 2.4-ered VEGF provide different signaling outcomes even though dinitrofluorobenzene (DNP; quencher) at the carboxy terminus they act through the same cell surface receptor (VEGFR2). to create a fluorescent peptide indicator of MMP activity. When
The role of multiple VEGF-A isoforms, which moduintact, the peptide indicator did not emit a signal. Upon cleavlates the interaction of VEGF with the matrix, has remained age by MMP3. a strong fluorescence signal was recorded (Fig. elusive. Using tumor cells with low levels of endogenous 7 A). Inclusion of the wild-type peptide in fibrinogen gel assays VEGF, Grunstein et al. (2000) introduced VEGF120, 164. and revealed discrete areas of fluorescence in proximity to cells that 188 isoforms individually and tested their effects in tumor aninvaded the gel, indicating that cleavage of the peptide had ocgiogenesis. Although the approach did not eliminate endogecurred (Fig. 7 B) . No cleavage was detected when BB94 was nous VEGF from the invading stroma, the authors noted subincluded in the gel. Similarly, the mutant peptide lacking the stantial differences in the vascularization of the tumors. In cleavage site did not show a signal. Together. these results sugparticular, VEGF 1 a displayed an extensive hypervascular regest that MMP cleavage of VEGF occurs in discrete. extracelsponse in comparison with the other isoforms (Grunstein et lular microdomains and results in distinct signaling outcomes. al., 2000) . Subsequently. in a series of experiments. Ruhrberg These in vitro findings are consistent with the effect of the difet al. (2002) developed isoform-specific VEGF mice, revealferent VEGF forms in tumors. Hyperplasia would be analogous ing that VEGF-A isoforms play a critical role in the guidance to proliferation of cells as sheets (cleaved VEGF), whereas the of vascular patterning and in vessel diameter during developinvasion and morphogenesis of cords is analogous to active ment . Thus, mice expressing VEGFI 2 0 sprouting angiogenesis (uncleaved. matrix-tethered VEGF).
displayed lower vascular density, poor sprouting, and filopodia extension. In contrast, the sole expression of VEGFIg D iscussion leads to increased multidirectional filopodia extension, higher vascular density, and disorganized patterning. Interestingly. We investigated the potential role of MMPs in the generation mice that were heterozygous for both isoforms showed a -norof bioactive VEGF from extracellular stores. In the process. we mealized" vasculature. suggesting that matrix association plays found that VEGF can be cleaved intramolecularly by a subset a role in vascular density and patterning.
[08] TO BE PROVIDED' - it has been proposed that the longer isoforms (189 and 206) are proteolytic processing. The second mode would directly dehindered from inducing the activation of VEGF receptors and pend on microenvironmental levels of specific MMPs/plasmins that cleavage events are required for the induction of mitogenic and could add more precise regulation than splicing alone, activities in endothelial cells (Houck et al., 1991) . Given the preponderance of MMPs during pathological condiIn the process of elucidating the contribution of proteintions, we would predict that extracellular processing is likely to ases to the release of VEGF, we also confirm earlier reports be a frequent regulatory event during tissue repair, inflammathat matrix-bound VEGF is active Poltorak tion, and in cancer (Coussens and Werb, 2002) . In fact, the relet al., 1997; Hutchings et al., 2003) . However, we note that the ative levels and availability of MMPs can offer an explanation outcome of receptor activation mediated by soluble and bound for the heterogeneous nature of vessels in different tumors.
VEGF was different. Although both forms were similarly capaThus, discrete levels of MMPs could have an impact on VEGF ble of phosphorylating VEGFR2, they elicited different cellular signaling, resulting in alterations in vascular density, vessel diresponses by this same receptor. MMP-resistant/matrix-bound ameter, and patterning through the direct alteration in the status VEGF induced filopodia extension, discrete invasion of the of bound versus soluble VEGF. The concept that MMPs regustroma, and facilitated cell-cell associations that were consislate the local distribution of VEGF has also been noted in a tent with tube formation; i.e., sprouting angiogenesis. In conmodel of retinopathy in mice (Gerhardt, H., and C. Betsholtz, trast, cleaved VEGF resulted in the proliferation of cells as personal communication), Their findings provide evidence that sheets and in the broad invasion of the stroma, which is consis-MMP activity is linked to a cascade of events that regulate tent with vascular hyperplasia. These findings could offer a VEGF and vascular patterning, handle on how to dissect the wealth of signaling pathways that Our results do not negate the possibility that the proteolyare activated by VEGF. This growth factor has been implicated sis of matrix molecules might also lead to the release of VEGF in the induction of permeability, proliferation, migration, diffrom extracellular stores. However, these events deserve a ferentiation, and morphogenesis. Although it is clear that all more detailed investigation, as does the nature of the interacthese signaling outcomes do not occur simultaneously, it has tions between VEGF and specific matrix molecules. Also, it is been difficult to ascertain the hierarchy of the effects and important to stress that several MMPs were found to mediate when/how one response prevails over others. VEGF processing. 4 out of 13 MMPs tested were effective in Angiogenesis is a complex, multifactorial phenomenon severing VEGF from the matrix via specific intramolecular involving signals from endothelial cells and from the host tiscleavage. Thus, it is likely that these effects are highly redunsue. Although the key players in this process have been identidant in vivo.
fled, and their specific roles are being elucidated individually, a MMPs play a significant role in matrix remodeling, enconcrete understanding of the process will only come from the abling migration, and the establishment of new capillary beds comprehensive acknowledgment that they act as a whole in a (Heissig et al., 2003) . Understanding the interplay between series of dynamically reciprocal interactions that modulate sigthese molecules and the reciprocal effects on the tumor vascunaling outcomes. lature has been a major effort in the field. (Pozzi et al., 2000) by the production alytically active forms of MMP2, 3, 7, 8, 9 , MT1-MMP (MMP14), MT3-MMP (MMP16), ADAMTS4, and plosmin were purchased from Calbiaof angiogenesis inhibitors via proteolysis and other mechachem. The activity of MMPs was tested against known substrates before nisms (O'Reilly et al., 1999; Hamano et al., 2003 Digestion of VEGF Unless specified, VEGF was incubated with proteinases in incubation buffer In viva Matrigel plug assay (50 mM TrisCI, pH 7.45, 150 mM NaCI, 10 mM CaCI2, and 1 tim ZnCI2) 6-wk-old female nude mice (Charles River Laboratories) were anesthesized at a 4"1 molar ratio (VEGF/proteinases) at 37*C for 4 h. To biotinylate with avertin, were subcutaneously injected with 250 PI of growth factormVEGF 164 , 5 ILg VEGF was incubated with 1 mg/ml sulfo-N-hydroxy sucreduced Matrigel (BD Biosciences), and were supplemented with either secinimido-biotin-long chain (Pierce Chemical Co.) overnight at 4'C, and rum-free DME or with 1 ý,g VEGF. After 7 d, the mice were killed, and the the reaction mixture was dialyzed in 1 x PBS to eliminate free biotin. For angiogenic response was evaluated, Matrigel plugs were fixed in 1% heparin-bound VEGF assays, plates were coated with 5 tg/ml heparin folparaformaldehyde, and vessels were detected with a rat anti-mouse lowed by biotinyloted VEGF, were washed, and were exposed to [03]
CD31 antibody followed by Cy34abeled goat anti-rat lgG antibody (both vehicle or enzyme. Biotinylated VEGF reaction mixtures were analyzed by purchased from Jackson ImmunoResearch Laboratories). Evaluation was using 20% tricine-Tris gel, followed by avidin D coupled with HRP (Vector performed on a confocal microscope (model MRC-1 024; Bio-Rad LaboraLaboratories), and were visualized by chemiluminescence. Whenever nontories). biotinylated VEGF was used, products were either analyzed on silverstained gel or were immunoblotted using anti-VEGF antibodies.
Xenograft tumor assays T47D and HT1080 cell lines were injected subcutaneously (5 x 106 cells) VEGF purification from ascites fluid in 6-wk-old female nude mice (Charles River Laboratories). Tumor growth Ascites fluid was collected from ovarian cancer patients with the approval was monitored every other day. When tumors reached 1,500 mm?, mice of the Institutional Review Board (a gift of Joseph Mortola and Michael were killed, and dissected tumors were solubilized in lysis buffer as deGraubert, Beth Israel Deaconess Medical Center). No patient identifiers scribed previously (Rodriguez-Monzaneque et al., 2001) . A total of 42 were retained. VEGF immunoaffinity column was prepared with polymice were injected with T47D, 42 mice were injected with T47D-expressclonal VEGF antibody (provided by Donald Senger). Ascites samples were ing mVEGFIM, 47 mice were injected with T47D-expressing mVEGF 1 m 3 , loaded onto the column, were washed in binding buffer, and were eluted and 45 mice were injected with T47D-expressing mVEGF1 0g s. A total with NaCI 2 . The presence of VEGF in eluted fractions was assessed by imof 60 mice were injected with HT1080, HT1080-expressing mVEGF 1 6, munoblotting with VEGF antibodies. mVEGF 113 , and mVEGFAoa.-iis (15 mice each). Nude mice that were injected with T47D-expressing mVEGF 1 6 were used for BB94 treatment. Amino-terminal amino acid sequencing and MS analysis BB94 was homogenized in PBS, pH 7.0, containing 0.02% Triton X-100 MMP3-cleaved mVEGFj6 was separated by 20% tricine-Tris gel electroand was administered as an emulsion by intraperitoneal injection. Mice phoresis and was transferred onto polyvinylidene difluoride membranes (cohort of five animals per group) were treated daily with 30 mg/kg for a by using 3-[cyclohexylamino]-l-propanesulfonic acid buffer. The resulting total of 5 d. 16-and 6-kD VEGF fragments were amino-terminally sequenced using a microsequenator (model 477A; Applied Biosystems), which was a service EUISA provided by William Lane (Harvard Microchemistry Facility, Cambridge, To quantify levels of VEGF in the serum, blood samples were collected and MA). For MS and microsequencing analyses, nonglycosylated mVEGF1 6 A allowed to clot overnight at 4°C. Samples were centrifuged at 2,000 9 for was incubated with catalytically active MMP3, and 13-kD fragments were 20 min. The serum was assayed by using a "sandwich' mouse VEGFanalyzed by using MALDI-TOF MS, ALC/MS", and iLC/MS/MS on a ELISA kit (Calbiochem) according to the manufacturer's instructions. To dequadrupole ion trap mass spectrometer (model Finnigan LCQ DECA; Hartect VEGF forms with intact carboxy termini, VEGF antibody 375 raised yard Microchemistry Facility). against amino acids coded by exon 8 was immobilized onto the surface of the [05] 96-well plastic wells and was assayed by using sandwich Construction of stable cell lines and purification of proteins ELISA. After normalization, a comparison of both ELISA assays revealed mVEGF-A cDNA isoforms 120, 164, and 188 were cloned into the levels of cleaved and uncleaved VEGF. To determine the VEGF levels pcDNA3.1 expression vectors (Invitrogen). For the construction of in tumor explant cultures, tumors were collected and incubated in 200 il mVEGF 113 , PCR was performed by using primer P1 (5'-CAAGCGCGCAA-DME containing 0.5% FBS, either in the presence or absence of MMP3 (1 GAGAGCGGG-3') and primer P2 (5'-TCACCGCCTTGGCTTGTCACATCng/Rl) or MMP3 (1 ng/gI) in the presence of BB94 (10 tIM). After 24 h 3'). Reverse primer P3 (5'-TCTCCGCCTTGGCTTGTCACATC-3') was used of incubation at 37°C, the conditioned medium was removed and asfor the construction of mVEGFi 13 hi,. The resulting product was subcloned sayed by using a sandwich mouse VEGF-ELISA kit (Calbiochem). into pCR-Blunt Il-TOPO vectors (Invitrogen), and the insert was substituted into the analogous site in pcDNA3.1 plasmids. For the construction of Immunohistochemical analysis mVEGFa10s-1is, sequential PCR was performed. Primer sets P1 and P4 (5'-Tumors were collected, fixed in 1% paraformaldehyde, and sectioned at GCTCTGAACAIICTTTGGTCTGCAT"C-3'), P5 (5'-GACCAAAGAAAT-200 ttm using a vibrotome (Ted Pella). The evaluation of skin near tumors GTTCAGAGCGGAGAAAGC-3'), and P2 were used for the initial PCR.
was performed as a whole-mount preparation. Vessels were visualized The resulting fragments were then amplified in a second PCR step by using with a rat anti-mouse CD31 antibody followed by Cy3-1abeled goat antiprimers P1 and P2. The final product was subcloned into pcDNA3.1 plasrat IgG antibody (both from Jackson ImmunoResearch Laboratories). The mids as described above.
evaluation was performed on a confocal system (model MRC-1024; Bio-HEK 293T, T47D, and HT1080 cells were tronsfected with 1 •g p.
Rod Laboratories). For hematoxylin and eosin staining, tumors were fixed cytomegalo virus-puro and 10 Ig pcDNA3.1 or with expression vectors in 4% poraformaldehyde, were paraffin embedded, sectioned, and using calcium phosphate. Selection was performed 48 h after transfection stained by members of the UCLA Tissue Core Laboratory. with 1.5 tig/ml puromycin. All stable clones were evaluated for proliferation rates (Fig. S2) . Recombinant mVEGF 1 6 and mVEGF 1 o,.e1 is were puriQuantitation of angiogenesis fied from the conditioned media of stable clones by heparin affinity chroQuantitotion of vascular density was performed from confocal immunmatography using fast protein liquid chromatography (Bio-Rad ostained images. Images were collected randomly (two images from each Laboratories). Recombinant mVEGF113, was purified by Co 2 ÷ chelate oftumor, CAM, or Matrigel; four to six individual samples were evaluated in finity chromatography. every case), and vascular density was determined with the aid of IM-AGEPRO 4.0 software (Media Cybernetics). Phosphorylation assays VEGFR2 phosphorylation was determined by immunoblotting as described
In vitro angiogenesis assay previously (Luque et al., 2003) .
Cytodex beads (712,000 beads/ml; Sigma-Aldrich) were incubated with PAE or with PAE-VEGFR2 cells and were then embedded into fibrinogen/ CAM assay fibronectin gel (2.5 mg/ml; Sigmo-Aldrich) containing 100 ng VEGF and The effect of mVEGF 1 6, mVEGF, 13 , and mVEGF 1 oe-11 a on angiogenesis 1 U/0i thrombin (Sigma-Aldrich). The extent of angiogenesis was evoluwas evaluated as previously described (Vazquez et al., 1999) . The colated on a fluorescent inverted microscope (model Diaphot 300; Nikon).
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